Data di Pubblicazione:
2021
Citazione:
In silico drug repurposing in COVID-19: A network-based analysis / P. Sibilio, S. Bini, G. Fiscon, M. Sponziello, F. Conte, V. Pecce, C. Durante, P. Paci, R. Falcone, G.D. Norata, L. Farina, A. Verrienti. - In: BIOMÉDECINE & PHARMACOTHÉRAPIE. - ISSN 0753-3322. - 142(2021), pp. 111954.1-111954.10. [Epub ahead of print] [10.1016/j.biopha.2021.111954]
Abstract:
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Corticosteroid; COVID-19; Drug repurposing; Heparin; Inflammatory bowel disease; Septic shock
Elenco autori:
P. Sibilio, S. Bini, G. Fiscon, M. Sponziello, F. Conte, V. Pecce, C. Durante, P. Paci, R. Falcone, G.D. Norata, L. Farina, A. Verrienti
Link alla scheda completa: